-transparent.png){kind=logo}
Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes. 1996
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
Department of Infectious Diseases, University of Vienna, Austria.
Cefpirome is a cephalosporin eliminated primarily by kidneys that requires dosage reduction in patients with renal failure. The pharmacokinetic parameters were studied in 10 patients with end-stage renal disease who were receiving hemodialysis. Repeated intravenous administration of 2 gm cefpirome three times a week resulted in trough levels of 12.2 +/- 5.4 micrograms/ml and peak serum concentrations of 99.6 +/- 82.1 micrograms/ml. After 3 1/2 hours of hemodialysis with polysulfone high-flux membranes, 62.3% +/- 23.3% of cefpirome was removed. The interdialytic half-life was 9.35 +/- 0.99 hours, and the intradialytic half-life was 2.02 +/- 0.7 hours.
Related Publications
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
May 1997,
Wiener klinische Wochenschrift,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
July 1994,
Clinical nephrology,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
September 2014,
Nursing and midwifery studies,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
January 2003,
Contributions to nephrology,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
July 1992,
Antimicrobial agents and chemotherapy,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
March 1992,
Journal of clinical pharmacology,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
July 1994,
Clinical nephrology,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
July 1992,
Clinical pharmacology and therapeutics,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
September 2011,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
F Thalhammer, and
S Schmaldienst, and
I Elmenyawi, and
M Atteneder, and
H Burgmann, and
U Hollenstein, and
A Georgopoulos, and
W Graninger, and
D Putz, and
A R Rosenkranz, and
G Mayer, and
W H Hörl, and
S Breyer
January 1985,
American journal of nephrology,
